{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:23:47Z","timestamp":1774538627004,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science-Technology Support Plan Projects in Sichuan Province","award":["2024YFFK0272, 2024NSFSC1711, 2024YFFK0078"],"award-info":[{"award-number":["2024YFFK0272, 2024NSFSC1711, 2024YFFK0078"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82370236"],"award-info":[{"award-number":["No. 82370236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["No. 2022 YFC2703902"],"award-info":[{"award-number":["No. 2022 YFC2703902"]}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"crossref","award":["2025ZNSFSC1674, 2025ZNSFSC0705"],"award-info":[{"award-number":["2025ZNSFSC1674, 2025ZNSFSC0705"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key research and development project of Chengdu Science and Technology Bureau","award":["2024-YF05-00237-SN, 2024-YF05-00506-SN"],"award-info":[{"award-number":["2024-YF05-00237-SN, 2024-YF05-00506-SN"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06141-5","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T12:58:54Z","timestamp":1745672334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of glucocorticoids on cardiac function of patients with Duchenne muscular dystrophy: benefit or not?"],"prefix":"10.1007","volume":"184","author":[{"given":"Yaru","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuran","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"1","key":"6141_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9(1):77\u201393","journal-title":"Lancet Neurol"},{"issue":"4","key":"6141_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347\u2013361","journal-title":"Lancet Neurol"},{"key":"6141_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13023-014-0220-7","volume":"10","author":"X Li","year":"2015","unstructured":"Li X, Zhao L, Zhou S, Hu C, Shi Y, Shi W, Li H, Liu F, Wu B, Wang Y (2015) A comprehensive database of Duchenne and Becker muscular dystrophy patients (0\u201318 years old) in East China. Orphanet J Rare Dis 10:5","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"6141_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7(1):13","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"6141_CR5","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","volume":"131","author":"EM McNally","year":"2015","unstructured":"McNally EM, Kaltman JR, Benson DW, Canter CE, Cripe LH, Duan D, Finder JD, Groh WJ, Hoffman EP, Judge DP, Kertesz N, Kinnett K, Kirsch R, Metzger JM, Pearson GD, Rafael-Fortney JA, Raman SV, Spurney CF, Targum SL, Wagner KR, Markham LW (2015) Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation 131(18):1590\u20138","journal-title":"Circulation"},{"issue":"6","key":"6141_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","volume":"20","author":"HJ Van Ruiten","year":"2016","unstructured":"Van Ruiten HJ, Marini Bettolo C, Cheetham T, Eagle M, Lochmuller H, Straub V, Bushby K, Guglieri M (2016) Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. Eur J Paedia Neurol\u202f: EJPN\u202f: Off J Eur Paedia Neurol Soc 20(6):904\u2013909","journal-title":"Eur J Paedia Neurol : EJPN : Off J Eur Paedia Neurol Soc"},{"issue":"4","key":"6141_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s00246-020-02309-y","volume":"41","author":"CA Wittlieb-Weber","year":"2020","unstructured":"Wittlieb-Weber CA, Knecht KR, Villa CR, Cunningham C, Conway J, Bock MJ, Gambetta KE, Lal AK, Schumacher KR, Law SP, Deshpande SR, West SC, Friedland-Little JM, Lytrivi ID, McCulloch MA, Butts RJ, Weber DR, Johnson JN (2020) Risk Factors for Cardiac and Non-cardiac Causes of Death in Males with Duchenne Muscular Dystrophy. Pediatr Cardiol 41(4):764\u2013771","journal-title":"Pediatr Cardiol"},{"key":"6141_CR8","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/DDDT.S110163","volume":"10","author":"S Miyatake","year":"2016","unstructured":"Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y (2016) Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Dev Ther 10:2745\u20132758","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"6141_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","volume":"16","author":"S Kourakis","year":"2021","unstructured":"Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E (2021) Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? Orphanet J Rare Dis 16(1):117","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"6141_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","volume":"72","author":"A \u0141oboda","year":"2020","unstructured":"\u0141oboda A, Dulak J (2020) Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacol Rep\u202f: PR 72(5):1227\u20131263","journal-title":"Pharmacol Rep : PR"},{"issue":"1","key":"6141_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JND-200556","volume":"8","author":"M Quattrocelli","year":"2021","unstructured":"Quattrocelli M, Zelikovich AS, Salamone IM, Fischer JA, McNally EM (2021) Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy. J Neuromusc Dis 8(1):39\u201352","journal-title":"J Neuromusc Dis"},{"issue":"5","key":"6141_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","volume":"77","author":"DM Escolar","year":"2011","unstructured":"Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, Kornberg AJ, Bertorini TE, Nevo Y, Lotze T, Pestronk A, Ryan MM, Monasterio E, Day JW, Zimmerman A, Arrieta A, Henricson E, Mayhew J, Florence J, Hu F, Connolly AM (2011) Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77(5):444\u2013452","journal-title":"Neurology"},{"issue":"12","key":"6141_CR13","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1212\/WNL.41.12.1874","volume":"41","author":"GM Fenichel","year":"1991","unstructured":"Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT 3rd, Griggs RC, Brooke MH, Miller JP, Robison J, King W et al (1991) Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41(12):1874\u20131877","journal-title":"Neurology"},{"issue":"11","key":"6141_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1177\/0883073810362762","volume":"25","author":"DJ Matthews","year":"2010","unstructured":"Matthews DJ, James KA, Miller LA, Pandya S, Campbell KA, Ciafaloni E, Mathews KD, Miller TM, Cunniff C, Meaney FJ, Druschel CM, Romitti PA, Fox DJ (2010) Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. J Child Neurol 25(11):1319\u20131324","journal-title":"J Child Neurol"},{"issue":"5","key":"6141_CR15","first-page":"Cd003725","volume":"2016","author":"E Matthews","year":"2016","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016(5):Cd003725","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"6141_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0883073810371004","volume":"25","author":"RT Moxley 3rd","year":"2010","unstructured":"Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K (2010) Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 25(9):1116\u20131129","journal-title":"J Child Neurol"},{"key":"6141_CR17","doi-asserted-by":"publisher","first-page":"120017","DOI":"10.1016\/j.watres.2023.120017","volume":"239","author":"L Varga","year":"2023","unstructured":"Varga L, Fenner K, Singer H, Honti M (2023) From market to environment - consumption-normalised pharmaceutical emissions in the Rhine catchment. Water Res 239:120017","journal-title":"Water Res"},{"key":"6141_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpeds.2016.11.078","volume":"182","author":"BL Wong","year":"2017","unstructured":"Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, Sawnani H, Jefferies JL (2017) Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. J Pediatr 182:296-303.e1","journal-title":"J Pediatr"},{"issue":"6","key":"6141_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0002-9149(02)03429-X","volume":"91","author":"CK Silversides","year":"2003","unstructured":"Silversides CK, Webb GD, Harris VA, Biggar DW (2003) Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91(6):769\u2013772","journal-title":"Am J Cardiol"},{"issue":"4","key":"6141_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","volume":"16","author":"WD Biggar","year":"2006","unstructured":"Biggar WD, Harris VA, Eliasoph L, Alman B (2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromusc Disord\u202f: NMD 16(4):249\u2013255","journal-title":"Neuromusc Disord : NMD"},{"issue":"3","key":"6141_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","volume":"38","author":"S Houde","year":"2008","unstructured":"Houde S, Filiatrault M, Fournier A, Dub\u00e9 J, D\u2019Arcy S, B\u00e9rub\u00e9 D, Brousseau Y, Lapierre G, Vanasse M (2008) Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 38(3):200\u2013206","journal-title":"Pediatr Neurol"},{"issue":"1","key":"6141_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejpn.2008.02.006","volume":"13","author":"S Mavrogeni","year":"2009","unstructured":"Mavrogeni S, Papavasiliou A, Douskou M, Kolovou G, Papadopoulou E, Cokkinos DV (2009) Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study. Eur J Paedia Neurol\u202f: EJPN\u202f: Off J Eur Paedia Neurol Soc 13(1):34\u201340","journal-title":"Eur J Paedia Neurol : EJPN : Off J Eur Paedia Neurol Soc"},{"issue":"5","key":"6141_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.nmd.2008.03.002","volume":"18","author":"LW Markham","year":"2008","unstructured":"Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH (2008) Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromusc dis\u202f: NMD 18(5):365\u2013370","journal-title":"Neuromusc dis : NMD"},{"issue":"4","key":"6141_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jpeds.2013.05.060","volume":"163","author":"BJ Barber","year":"2013","unstructured":"Barber BJ, Andrews JG, Lu Z, West NA, Meaney FJ, Price ET, Gray A, Sheehan DW, Pandya S, Yang M, Cunniff C (2013) Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 163(4):1080\u20134.e1","journal-title":"J Pediatr"},{"issue":"9","key":"6141_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","volume":"61","author":"G Schram","year":"2013","unstructured":"Schram G, Fournier A, Leduc H, Dahdah N, Therien J, Vanasse M, Khairy P (2013) All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 61(9):948\u2013954","journal-title":"J Am Coll Cardiol"},{"key":"6141_CR26","first-page":"1819","volume":"11","author":"L Zhang","year":"2015","unstructured":"Zhang L, Liu Z, Hu KY, Tian QB, Wei LG, Zhao Z, Shen HR, Hu J (2015) Early myocardial damage assessment in dystrophinopathies using (99)Tc(m)-MIBI gated myocardial perfusion imaging. Ther Clin Risk Manag 11:1819\u20131827","journal-title":"Ther Clin Risk Manag"},{"key":"6141_CR27","doi-asserted-by":"publisher","unstructured":"Tandon A, Villa CR, Hor KN et al (2015) Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc 4(4):e001338. https:\/\/doi.org\/10.1161\/JAHA.114.001338","DOI":"10.1161\/JAHA.114.001338"},{"issue":"1","key":"6141_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00246-004-0689-2","volume":"26","author":"C Kirchmann","year":"2005","unstructured":"Kirchmann C, Kececioglu D, Korinthenberg R, Dittrich S (2005) Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatr Cardiol 26(1):66\u201372","journal-title":"Pediatr Cardiol"},{"issue":"2","key":"6141_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mus.24163","volume":"50","author":"C Spurney","year":"2014","unstructured":"Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR (2014) Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50(2):250\u2013256","journal-title":"Muscle Nerve"},{"issue":"8","key":"6141_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.nmd.2017.05.019","volume":"27","author":"S Kim","year":"2017","unstructured":"Kim S, Zhu Y, Romitti PA, Fox DJ, Sheehan DW, Valdez R, Matthews D, Barber BJ (2017) Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. Neuromusc Dis\u202f: NMD 27(8):730\u2013737","journal-title":"Neuromusc Dis : NMD"},{"issue":"6","key":"6141_CR31","first-page":"875","volume":"62","author":"G Hussein","year":"2014","unstructured":"Hussein G, Mansour L, Ghafar HA, Mostafa FA, Fawaz L (2014) Short-term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies. J Investig Med Off Publ Am Federat Clin Res 62(6):875\u2013879","journal-title":"J Investig Med Off Publ Am Federat Clin Res"},{"issue":"4","key":"6141_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Bellgard MI, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Bari\u0161i\u0107 N, Brabec P, L\u00e4hdetie J, Walter MC, Schreiber-Katz O, Karcagi V, Garami M, Herczegfalvi A, Viswanathan V, Bayat F, Buccella F, Ferlini A, Kimura E, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Kostera-Pruszczyk A, Santos R, Neagu E, Artemieva S, Rasic VM, Vojinovic D, Posada M, Bloetzer C, Klein A, D\u00edaz-Manera J, Gallardo E, Karaduman AA, Oznur T, Topalo\u011flu H, El Sherif R, Stringer A, Shatillo AV, Martin AS, Peay HL, Kirschner J, Flanigan KM, Straub V, Bushby K, B\u00e9roud C, Verschuuren JJ, Lochm\u00fcller H (2017) Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database. J Neuromusc Dis 4(4):293\u2013306","journal-title":"J Neuromusc Dis"},{"issue":"6","key":"6141_CR33","doi-asserted-by":"publisher","first-page":"e16267","DOI":"10.1111\/ene.16267","volume":"31","author":"M Schiava","year":"2024","unstructured":"Schiava M, Lofra RM, Bourke JP, D\u00edaz-Manera J, James MK, Elseed MA, Malinova M, Michel-Sodhi J, Moat D, Ghimenton E, McCallum M, D\u00edaz CFB, Mayhew A, Wong K, Richardson M, Tasca G, Eglon G, Eagle M, Turner C, Heslop E, Straub V, Bettolo CM, Guglieri M (2024) Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids. Eur J Neurol 31(6):e16267","journal-title":"Eur J Neurol"},{"issue":"5","key":"6141_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/BF02731732","volume":"72","author":"S Gulati","year":"2005","unstructured":"Gulati S, Saxena A, Kumar V, Kalra V (2005) Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr 72(5):389\u2013393","journal-title":"Indian J Pediatr"},{"issue":"1","key":"6141_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mus.27490","volume":"66","author":"RJ Butterfield","year":"2022","unstructured":"Butterfield RJ, Kirkov S, Conway KM, Johnson N, Matthews D, Phan H, Cai B, Paramsothy P, Thomas S, Feldkamp ML (2022) Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet. Muscle Nerve 66(1):15\u201323","journal-title":"Muscle Nerve"},{"issue":"1","key":"6141_CR36","doi-asserted-by":"publisher","first-page":"e2260","DOI":"10.1002\/bdr2.2260","volume":"116","author":"KM Conway","year":"2024","unstructured":"Conway KM, Thomas S, Ciafaloni E, Khan RS, Mann JR, Romitti PA, Mathews KD (2024) Prophylactic use of cardiac medications for delay of left ventricular dysfunction in Duchenne muscular dystrophy. Birth Defects Res 116(1):e2260","journal-title":"Birth Defects Res"},{"issue":"6","key":"6141_CR37","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","volume":"26","author":"LW Markham","year":"2005","unstructured":"Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH (2005) Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26(6):768\u2013771","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"6141_CR38","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.chest.2020.04.043","volume":"158","author":"F Trucco","year":"2020","unstructured":"Trucco F, Domingos JP, Tay CG, Ridout D, Maresh K, Munot P, Sarkozy A, Robb S, Quinlivan R, Riley M, Burch M, Fenton M, Wallis C, Chan E, Abel F, Manzur AY, Muntoni F (2020) Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy: A Single-Site Retrospective Longitudinal Study. Chest 158(4):1606\u20131616","journal-title":"Chest"},{"issue":"1\u20132","key":"6141_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000227803","volume":"24","author":"SG Roy","year":"2009","unstructured":"Roy SG, De P, Mukherjee D, Chander V, Konar A, Bandyopadhyay D, Bandyopadhyay A (2009) Excess of glucocorticoid induces cardiac dysfunction via activating angiotensin II pathway. Cell Physiol Biochem Int J Exp Cell Physiol, Biochem Pharmacol 24(1\u20132):1\u201310","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol, Biochem Pharmacol"},{"issue":"2","key":"6141_CR40","doi-asserted-by":"publisher","first-page":"e88360","DOI":"10.1371\/journal.pone.0088360","volume":"9","author":"PM Janssen","year":"2014","unstructured":"Janssen PM, Murray JD, Schill KE, Rastogi N, Schultz EJ, Tran T, Raman SV, Rafael-Fortney JA (2014) Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. PLoS ONE 9(2):e88360","journal-title":"PLoS ONE"},{"issue":"2","key":"6141_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcm.2009.04.006","volume":"19","author":"D Townsend","year":"2009","unstructured":"Townsend D, Yasuda S, Chamberlain J, Metzger JM (2009) Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy. Trends Cardiovasc Med 19(2):50\u201355","journal-title":"Trends Cardiovasc Med"},{"key":"6141_CR42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","volume":"136","author":"LS Conklin","year":"2018","unstructured":"Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR (2018) Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res 136:140\u2013150","journal-title":"Pharmacol Res"},{"key":"6141_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","volume":"134","author":"EP Hoffman","year":"2018","unstructured":"Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM (2018) Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134:43\u201352","journal-title":"Steroids"},{"issue":"13","key":"6141_CR44","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","volume":"93","author":"EP Hoffman","year":"2019","unstructured":"Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Siener C, Jaros M, Shale P, McCall JM, Nagaraju K, van den Anker J, Conklin LS, Cnaan A, Gordish-Dressman H, Damsker JM, Clemens PR (2019) Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology 93(13):e1312\u2013e1323","journal-title":"Neurology"},{"key":"6141_CR45","doi-asserted-by":"publisher","unstructured":"Heier CR, Yu Q, Fiorillo AA, et al (2019) Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2(1):e201800186.https:\/\/doi.org\/10.26508\/lsa.201800186","DOI":"10.26508\/lsa.201800186"},{"issue":"9","key":"6141_CR46","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1007\/s00431-024-05670-9","volume":"183","author":"BC Henzi","year":"2024","unstructured":"Henzi BC, Lava SAG, Spagnuolo C, Putananickal N, Donner BC, Pfluger M, Burkhardt B, Fischer D (2024) Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy. Eur J Pediatr 183(9):4057\u20134062","journal-title":"Eur J Pediatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06141-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06141-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06141-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T20:03:02Z","timestamp":1746907382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06141-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06141-5","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}